Oncolis B<4588.T>
The patent regarding the administration method of the tumor lysis adenovirus "OBP-301" that the company applied for has been granted patent approval in Japan. The patent expires in May 2040. There are plans to apply for approval for "OBP-301" as a regenerative medical product for esophageal cancer within this December. The stock price experienced a rise in the morning before losing value.
Basis<4068.T>
A significant continuation of the rise updated the high price last year. Starting from June 30th and December 31st each year, a shareholder benefit system will be introduced for shareholders holding 200 shares or more recorded on the shareholder...
Comment(0)
Reason For Report